GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
Synonyms: compound 14g [PMID: 34813882] | DWP-16001 | DWP16001 | Envlo® | GCC-5694A | GCC5694A
enavogliflozin is an approved drug
Compound class:
Synthetic organic
Comment: Enavogliflozin (DWP16001) is a selective and competitive sodium/glucose cotransporter 2 (SGLT2; SLC5A2) inhibitor [1]. It exhibits a high affinity, sustained interaction with SGLT2, and is converted to two active metabolites that contribute to its efficacy [3]The structure is identical to that of GCC5694A which was disclosed in early 2022 [2].
![]() Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
References |
1. Choi MK, Nam SJ, Ji HY, Park MJ, Choi JS, Song IS. (2020)
Comparative Pharmacokinetics and Pharmacodynamics of a Novel Sodium-Glucose Cotransporter 2 Inhibitor, DWP16001, with Dapagliflozin and Ipragliflozin. Pharmaceutics, 12 (3): 268. [PMID:32183468] |
2. Kong YK, Song KS, Jung ME, Kang M, Kim HJ, Kim MJ. (2022)
Discovery of GCC5694A: A potent and selective sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes. Bioorg Med Chem Lett, 56: 128466. [PMID:34813882] |
3. Park SH, Ji HY, Choi JS, Oh KS, Lee J, Pang M, Song IS, Park JS. (2025)
Reverse translational approach to clarify the strong potency of enavogliflozin, a novel sodium-glucose cotransporter 2 inhibitor. J Pharmacol Exp Ther, 392 (8): 103650. [PMID:40706136] |